Switching Platelet P2Y12 Receptor Inhibiting Therapies.

Abstract

Antiplatelet therapy involving aspirin and a P2Y₁₂ receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y₁₂ inhibitors is frequently observed in clinical settings for various reasons, such as safety, efficacy, patient adherence, or cost concerns. Although it occurs often, the optimal method for switching remains a concern owing to potential drug interactions, which can result in either inadequate platelet inhibition and subsequent thrombotic events or low platelet reactivity and increased bleeding risks due to therapy overlap. This review offers practical guidance on switching P2Y₁₂ inhibitors, drawing from pharmacodynamic and clinical data.